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Resumo
Introdução:  O cancro da mama representa uma 
das principais causas de morte a nível mundial, 
porém, apesar da tendência de aumento da 
incidência desta patologia com o avançar 
da idade, persiste uma lacuna na adequada 
caracterização desta doença nas mulheres com 
idades mais avançadas. Objetivo: Caracterização 
clínica, imagiológica e histológica da patologia 
tumoral mamária em mulheres de idade igual 
ou superior a 80 anos e comparação com uma 
população representativa de idades inferiores. 
Métodos: Estudo unicêntrico retrospetivo de 
dados clinico-epidemiológicos, imagiológicos e 
histopatológicos de mulheres com idade igual ou 
superior a 80 anos, submetidas a estadiamento 
por ressonância magnética mamária e 
comparação com uma população representativa 
de mulheres com idades inferiores a 80 anos. 
Resultados: As doentes mais idosas apresentam-
se com doença em estádios mais avançados, 
existindo uma diferença estatisticamente 
significativa em relação ao estadiamento clínico 
entre os dois grupos (P-Value = 0.004). As 
mulheres com idades inferiores a 80 anos têm 
maior prevalência de carcinoma ductal in situ 
(P-Value = 0.02), com maior extensão de doença 
nestes casos (P-Value = 0.025). Os casos de 
CDIS em mulheres com idade avançada estão 
mais frequemente associados com positividade 
para os recetores de estrogénio (P-Value = 
0.03). Existe uma concordância moderada entre 
o estadiamento por ressonância magnética 
e o estádio patológico tanto no grupo das 
mulheres com idade superior ou igual a 80 anos 
(Kappa=0.50) como no grupo das mulheres 
em faixas etárias inferiores (Kappa=0.55). 
Conclusão: O cancro da mama nas mulheres 
com idade avançada apresenta características 
diferentes da patologia tumoral mamária em 
doentes de faixas etárias inferiores. 
Palavras-chave
Neoplasias da mama; Carcinoma ductal in situ; 
Carcinoma ductal; Imagem por ressonância 
magnética.
Abstract
Background: Breast cancer is a leading cause 
of  death worldwide, and despite consistent 
observation that cancer incidence increases 
with advancing age, there still remains a gap in 
the adequate characterization of  this disease in 
elderly women. Purpose: Characterization of  
the clinical, imaging and histological features 
of  breast cancer in women aged 80 years or 
older and comparison with features from 
a representative group of  younger women. 
Methods:  Single-center retrospective analysis of  
clinical, imaging and histopathological findings 
of  women aged 80 years or older submitted to 
magnetic resonance imaging and comparison 
with a representative population of  women 
under 80. 
Results:  Older patients have more advanced 
disease at presentation, with a significant 
difference in the clinical stage distribution 
between the two groups (P-Value = 0.004). 
Younger patients have a higher prevalence 
of  ductal carcinoma in situ (P-Value = 0.02), 
with more extensive DCIS disease (P-Value = 
0.025). DCIS in patients of  80 years or older 
is more frequently associated with positive 
estrogen receptors (P-Value = 0.03). Moderate 
agreement was found in the concordance 
between the clinical stage according to breast 
MR imaging and the pathological stage in 
patients of  80 years or over (Kappa = 0.50) and 
in younger aged patients’ group (Kappa = 0.55). 
Conclusion: Breast cancer in elderly women 
presents different characteristics from those in 
younger aged patients.
Keywords
Breast neoplasms; Carcinoma intraductal 
noninfiltrating; Carcinoma ductal; Magnetic 
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Introduction
Cancer is a leading cause of  death worldwide, with breast 
cancer being the most commonly occurring cancer in women 
globally. Despite consistent observation that the cancer 
incidence increases with advancing age, there still remains a 
gap in the adequate characterization of  this disease in elderly 
women.
This study aims to characterize the clinical, imaging and 
histological features of  breast cancer in women aged 80 
years or older and comparing them with features from a 
representative group of  younger women.
Material and methods
Inclusion criteria for the study were patients with 
histologically confirmed breast cancer under staging by 
6magnetic resonance (MR) imaging. This retrospective study 
included a total of  240 women, comprising 87 women of  
80 years or older who performed MR staging between 
January 2016 and December 2017 and 153 women under 
the age of  80, corresponding to all the female patients in 
this age group who underwent cancer staging by breast 
MR, in the first semester of  2016. 
The following clinical, imaging and histopathological 
findings were analyzed and compared between the 
two groups of  patients: age, tumor size and extension, 
lymph node status, presence of  metastatic disease, 
multifocality and multicentricity, histological type, degree 
of  differentiation, immunohistochemical characteristics, 
molecular subtype and cellular proliferation status. The 
tumor staging determined by MR was compared with the 
pathological staging (in patients submitted to radical or 
conservative surgery).
Statistical analysis
Statistical analysis was performed using the computing 
environment R (R Core Team, 2014). Categorical variables 
were compared using the chi-square test, while numeric 
variables were compared with a t-test, or with the Wilcoxon 
test, in case of  non-normality. The agreement between 
radiological and pathological stage was measured using the 
Cohen’s kappa coefficient. 
Results
In the 240 women included in the present study, fourteen 
patients had bilateral breast tumors at staging, with a total 
of  254 tumors evaluated. The mean age of  the oldest 
group was 83.6 years (minimum 80, maximum 94) and 57.6 
years (minimum 27, maximum 79) in the younger group. 
In terms of  classification by histological type, invasive 
ductal carcinoma not otherwise specified was the most 
prevalent in both age groups, representing 76.4% of  the 
cases in women under 80 and 72.2% of  the cases in the 
older group. Specific forms of  invasive carcinoma were 
identified in 12.1% and 20.6% of  the cases, among which 
invasive lobular carcinoma was the most frequent, present 
in 5.1% of  the cases of  women under 80 years and 6.2% 
of  the younger population group. Ductal carcinoma in situ 
(DCIS) was the histological diagnosis in 11.5% and 7.2%, 
with a statistically significant predominance (P-Value = 
0.02) in the population of  less than 80 years. 
The cases of  invasive tumors (Figure 1) had an average size 
of  28.2 mm in women aged 80 years or older, with the mean 
tumor size in the group of  younger women being 24.3 mm, 
revealing a trend, albeit not statistically significant for the 
sample size (P-value = 0.145), of  more extensive disease 
in the older aged group of  patients. The tumor extension 
of  DCIS cases (Figure 2) shows a statistically significant 
difference (P-Value = 0.025), with more extensive disease 
in the younger group of  patients (mean size of  31.3mm) 
than in the group of  women aged 80 years or older (mean 
size of  15.6mm). 
The majority of  the cases of  older women were in the initial 
stages of  the disease (stage IA 26.7%, stage IIA 44.2%, 
stage IIB 10.5%) and presented stage III in 12.1% of  the 
cases. Metastatic disease was documented in only 3 cases. 
In the study group of  women younger than 80 years, most 
cases represented disease in the earliest stages of  the disease 
(IA stage 35.3%, stage IIA 21.6%, stage IIB 15.7%), with a 
single case of  metastatic disease, representing a statistically 
significant difference in the distribution of  stages between 
the two groups (P-Value = 0.004).
Most cases of  invasive tumors were moderately 
differentiated carcinomas (G2), with undifferentiated 
disease (G3) representing the second most frequent 
tumor grade found in both groups. Hormonal positive 
disease (estrogen and progesterone receptor positivity) was 
predominant, with no statistically significant differences 
being documented in the histological and immuno-
histochemical characterization of  both groups (Table 1).
The molecular subtype distribution of  invasive and in situ 
carcinomas according to the 2013 St. Gallen consensus was 
evaluated (Figure 3), with a significant difference found 
(P-Value = 0.03) between the two groups regarding the 
prevalence of  DCIS with and without estrogen receptors. 
In relation to invasive tumors, there is no difference in 
the distribution between the two groups, and there was 
an overall predominance of  carcinomas with Luminal B 
HER2 Negative subtype. 
Figure 1 – Invasive carcinoma dimensional distribution.
Figure 2 – In situ carcinoma dimensional distribution.
7The largest tumor diameter represents a crucial prognostic 
factor in breast cancer patients,12 and we found that the 
older age group had a tendency to present in the clinical 
staging, by breast MR, larger tumors than younger patients, 
findings that are supported by the available scientific 
evidence.13–15
Regarding DCIS size we found the inverse relationship, in 
patients younger than 80 years, presenting larger carcinoma 
in situ (31.3mm vs 15.6 mm). The literature does not 
provide adequate data regarding DCIS extension in elderly 
women, having most studies focused on the management 
and treatment of  these patients, namely the use of  isolated 
surgery versus surgery and radiotherapy in the cases of  low 
grade and smaller size DCIS.16 
Regarding the histologic type, invasive ductal carcinoma 
not otherwise specified is the most prevalent type of  tumor 
diagnosed (72.2% of  the cases in the older age group), 
with tumors having special histological features identified 
relatively often (20.6%). However, we found a lower 
percentage of  lobular carcinomas (5.1% of  the cases) when 
compared to the available data in the literature, ranging up 
to 17% of  the cases as described by Fisher et al. in a cohort 
of  382 women over 70 years of  age.6 Papillary carcinoma 
was the histological diagnosis in 4 women aged 80 or older 
in our study (4.5%), representing a rare histological subtype 
with a favorable prognosis and with a reported higher 
incidence in the elderly.17,18 Another subtype with favorable 
prognosis is the mucinous carcinoma, which was found in 
4.5% of  the patients in the older age group of  our cohort, a 
lower percentage when compared to the reported incidence 
in other studies of  women in this age group, which ranges 
from 4.9% to 16%.11,19
The histological grade of  the tumor is regarded as a crucial 
prognostic factor, with correlation to the disease free and 
overall survival times.3 Our study did not find statistical 
differences between both age groups regarding tumor 
differentiation, the majority of  the cases consisting of  
moderately differentiated carcinomas (G2), representing 
64.4% of  the cases of  older aged women, findings in line 
with other studies published.11,14 Regarding undifferentiated 
disease, we found a total of  21 cases (23.3%) in women 
aged 80 or older, and the results are not homogeneous in 
the literature, with some reporting a lower prevalence of  
higher grade carcinoma (16.8% in the study by Chatzidaki 
et al.) and others finding a higher number of  cases of  
undifferentiated breast carcinoma, ranging from 28% to 
37%.11,13,20
Regarding hormone receptor status, multiple studies 
have shown that older patients are more likely to have 
hormone receptor-positive breast carcinoma,5,10,21,22 and 
that Estrogen Receptor (ER) positive and Progesterone 
Receptor (PR) positive disease leads to a lower risk of  
breast cancer-specific mortality compared to ER-negative 
and PR-negative tumors.23 In our study, ER and PR status 
was evaluated in all patients of  the advanced age group 
with invasive carcinoma, with the majority being ER-
positive (76%) and PR-positive (55,6%). Similar incidence 
In terms of  imaging, the statistical analysis of  the 
concordance between the clinical stage according to 
breast MR imaging and the pathological stage (in patients 
submitted to radical or conservative surgery) revealed a 
moderate agreement in both the group of  women with 
80 years or older (Kappa = 0.50) and the younger aged 
patients group (Kappa = 0.55).
Discussion
The Portuguese population is aging and in 2080 the 
number of  Portuguese individuals aged 65 years and 
older is projected to be 3.3 million (more than 50% of  the 
estimated 2.1 million in 2016).1
Although breast cancer incidence peaks in women aged 
70–79 years (452 cases/100,000 women in the United 
States of  America), a fifth of  all new breast cancer cases 
occurs in the older women group (aged 75 years or older). 
A 75 year old woman of  average risk who has been breast 
cancer free, still has a 5.2% probability of  developing breast 
cancer during the rest of  her lifetime.2
Breast cancer represents a heterogeneous disease, with 
multiple distinct subtypes identified according to the 
different pathological, biological, and clinical characteristics 
presented.3,4
The issue of  breast cancer characterization in patients of  
advanced age is a controversial topic, with some authors 
stating that it has a tendency to show less aggressive 
features, but the lack of  scientific data regarding the clinical, 
imaging and histological characteristics of  breast carcinoma 
in the very elderly female population (80 years old or older) 
hinders the ability to produce adequate statistical analysis 
and conclusions in this setting.5–7
When compared to younger aged women, breast cancer 
in older women exhibits some different histological and 
biological characteristics, with a variety of  combinations of  
favorable and less favorable features, as shown in our work 
and in agreement to other studies already published.8,9
The largest number of  tumors in the older aged group were 
invasive carcinomas (92.8%), while only 7.2% of  the cases 
represented carcinoma in situ, in accordance to reports of  
reduced incidence of  DCIS in elderly women.10,11
Age
Group
Tumor differentiation Estrogen Receptor Progesterone Receptor HER2 Ki-67
G1 G2 G3 N/A Pos. Neg. N/A Pos. Neg. N/A Pos. Neg. N/A High Low N/A
< 80 21 88 23 7 114 21 5 82 52 5 17 117 5 81 58 5
> 80 10 58 21 1 68 22 - 50 40 - 14 76 - 56 34 -
Figure 3 – Molecular subtypes of  invasive carcinoma and DCIS.
Table 1 – Histological and immunohistochemical characterization of  invasive carcinomas.
8of  ER positivity was previously reported on women aged 
75 years or older (74%)24 and ≥80 years (72% and 76%).7,11 
Although no statistical difference was found between 
immunohistochemical characterization of  both groups 
in invasive tumors, a study including more than 10,000 
patients, showed a higher incidence of  ER-positive tumors 
in women aged over 50 years (81%) when compared to 
women under 50 years (63%).25
Many authors reported that older women initially present 
more advanced tumor stages,26 and we found that the group 
of  women aged 80 years or older presented higher tumor 
stages (44.2% - stage IIA) more frequently when compared 
to the younger population studied (35.3% - stage IA). A 
study by Lyman et al.21 also showed that women of  older 
age (65 years or older) were more likely to have advanced 
stage cancer when compared to female patients with less 
than 65 years. A crucial factor associated with earlier staging 
at the time of  diagnosis is the use of  mammography, whose 
benefit proves true even for the elderly women.27–29 The use 
of  screening mammography leads to a reduction of  breast 
cancer mortality by detecting breast cancers when tumors 
are small and node negative, with pooled estimates from 
randomized controlled trials revealing a reduction of  at 
least 20% in mortality in women aged 74 years or younger,30 
and a meta-analysis of  European observational studies 
showing a decrease in breast cancer mortality by 38–48% in 
women who actually were screened.31 Regarding older aged 
women, a cohort of  more than 12000 women found that 
patients with breast cancer aged 80 years or older were 0.37 
times less likely to have an advanced stage at presentation 
for each previous mammogram performed.27
Regarding the performance of  mammography in this group 
of  patients, screening exams have a higher detection rate for 
invasive cancer when compared to younger women, aspects 
related both to the normal decrease of  breast density with 
age and higher incidence of  breast tumors in the elderly.32 
The sensitivity and specificity of  screening mammography 
is significantly higher in older women when compared to 
the lower aged patients and they experience fewer false-
positives in mammography and biopsies.33
Albeit the use of  screening programs with mammography 
is of  renown scientific validity, there is a lack of  consensus 
in the multiple professional societies and organizations 
regarding the optimal interval between examinations, the 
adequate timing to initiate and when to discontinue the 
screening.34 The existence of  compelling data regarding the 
potential to decrease breast cancer morbidity and mortality 
in older women, with studies showing that screening 
performance improves with age,35 improves prognosis 
and 10-year survival in women 75 years old and older36 
and improves life expectancy in older women without 
severe comorbidity,37 are compelling arguments for the 
termination of  any specific upper age limit in screening 
mammography programs.
Regarding preoperative staging of  breast cancer, all the 
patients enrolled in the present study were submitted to 
breast MR evaluation and statistical analysis revealed a 
moderate agreement of  the concordance between imaging 
and pathological staging, in both the group of  patients of  
80 years or older and the group of  younger women.
The use of  MR imaging in the breast evaluation is a well-
researched subject, with proven high sensitivity in breast 
cancer diagnosis and screening, and the use of  MR is 
increasingly being evaluated and used in the preoperative 
staging of  breast cancer. A systematic review and meta-
analysis of  the accuracy of  MR imaging in the detection 
of  breast cancer multifocal (MF) and multicentric (MC) 
extension showed that MRI detects additional disease in 
the same breast in 16% of  women, leading to an adequate 
surgical planning, with the pool of  studies demonstrating 
the use of  more extensive local surgery in 11.3% of  patients 
and conversion to mastectomy in 8.1% of  all patients with 
MF/MC disease, although the establishment of  the clinical 
value of  detecting additional disease in these patients is still 
under evaluation.38
Adequate evaluation of  regional lymph node status is of  
paramount importance for staging, treatment planning, 
and prognosis. The use of  MR imaging for breast cancer 
staging allows for evaluation of  nodal involvement, not 
only in the axillary region but also in the detection of  
internal mammary and supraclavicular adenopathy. The 
impact of  MR staging in the management of  these patients 
is very high, allowing for adequate guidance of  biopsy 
in abnormal axillary lymph nodes and confirmation of  
internal mammary nodal metastases, leading to an optimal 
staging and therapeutic planning.39
Conclusion
Women aged 80 years or older are more likely to present 
more advanced initial stage disease and tend to have larger 
invasive carcinomas in the staging exams. Ductal carcinoma 
in situ is less prevalent and shows smaller dimensions in 
the group of  patients of  80 years or older, more often 
presenting positive estrogen receptors. 
There are no significant differences regarding the 
tumor biological profile/molecular subtypes of  invasive 
carcinomas between the study groups and a moderate 
agreement was found between the radiological staging by 
MR imaging and the pathological staging in the women 
submitted to surgical treatment. 
Older patients with breast cancer lack adequate 
representation in the current medical literature and 
additional studies are required in order to clarify the 
different characteristics of  breast cancer in this population.
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